Chemical structure of molecule Venglustat Sanofi glucosylceramide synthase (GCS) inhibitor

potential BIC oral GCS inhibitor

Ph. III in genetic diseases (15 mg QD)

brain-penetrant, allosteric inhibitor

Scientific Reports


The Sanofi glucosylceramide synthase (GCS) inhibitor, venglustat, is an oral, brain-penetrant clinical candidate for GBA-mutant Parkinson’s disease and other diseases where GBA-mutations are relevant. Though the molecule did not demonstrate efficacy within…

 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.